BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 23580256)

  • 1. Correlation of immunohistochemical markers and BRAF mutation status with histological variants of papillary thyroid carcinoma in the Korean population.
    Min HS; Lee C; Jung KC
    J Korean Med Sci; 2013 Apr; 28(4):534-41. PubMed ID: 23580256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor overexpression is a marker for adverse pathologic features in papillary thyroid carcinoma.
    Fisher KE; Jani JC; Fisher SB; Foulks C; Hill CE; Weber CJ; Cohen C; Sharma J
    J Surg Res; 2013 Nov; 185(1):217-24. PubMed ID: 23746767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness.
    Kurtulmus N; Duren M; Ince U; Cengiz Yakicier M; Peker O; Aydın O; Altiok E; Giray S; Azizlerli H
    Endocrine; 2012 Oct; 42(2):404-10. PubMed ID: 22426956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
    Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
    Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid Rodolico V; Cabibi D; Pizzolanti G; Richiusa P; Gebbia N; Martorana A; Russo A; Amato MC; Galluzzo A; Giordano C
    Cancer; 2007 Sep; 110(6):1218-26. PubMed ID: 17685465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between BRAF V600E mutation and regional lymph node metastasis in papillary thyroid carcinoma.
    Lu J; Gao J; Zhang J; Sun J; Wu H; Shi X; Teng L; Liang Z
    Int J Clin Exp Pathol; 2015; 8(1):793-9. PubMed ID: 25755776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tall cell variant of papillary thyroid microcarcinoma: clinicopathologic features with BRAF(V600E) mutational analysis.
    Bernstein J; Virk RK; Hui P; Prasad A; Westra WH; Tallini G; Adeniran AJ; Udelsman R; Sasaki CT; Roman SA; Sosa JA; Prasad ML
    Thyroid; 2013 Dec; 23(12):1525-31. PubMed ID: 23682579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The synergic effect of BRAF
    Qu HJ; Qu XY; Hu Z; Lin Y; Wang JR; Zheng CF; Tan Z
    Endocr J; 2018 Jan; 65(1):113-120. PubMed ID: 29070763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Follicular variant of papillary thyroid carcinoma (FVPTC): histological features, BRAF V600E mutation, and lymph node status.
    Walts AE; Mirocha JM; Bose S
    J Cancer Res Clin Oncol; 2015 Oct; 141(10):1749-56. PubMed ID: 25702102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between expression of X-linked inhibitor of apoptosis protein and the clinical outcome in a BRAF V600E-prevalent papillary thyroid cancer population.
    Yim JH; Kim WG; Jeon MJ; Han JM; Kim TY; Yoon JH; Hong SJ; Song DE; Gong G; Shong YK; Kim WB
    Thyroid; 2014 Apr; 24(4):689-94. PubMed ID: 24124924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MUC1 expression in papillary thyroid carcinoma is associated with BRAF mutation and lymph node metastasis; the latter is the most important risk factor of relapse.
    Renaud F; Gnemmi V; Devos P; Aubert S; Crépin M; Coppin L; Ramdane N; Bouchindhomme B; d'Herbomez M; Van Seuningen I; Do Cao C; Pattou F; Carnaille B; Pigny P; Wémeau JL; Leteurtre E
    Thyroid; 2014 Sep; 24(9):1375-84. PubMed ID: 25012490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer.
    Jo YS; Li S; Song JH; Kwon KH; Lee JC; Rha SY; Lee HJ; Sul JY; Kweon GR; Ro HK; Kim JM; Shong M
    J Clin Endocrinol Metab; 2006 Sep; 91(9):3667-70. PubMed ID: 16772349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of molecular markers and tumor histological type in central lymph node metastasis of papillary thyroid carcinoma.
    Paulson L; Shindo M; Schuff K; Corless C
    Arch Otolaryngol Head Neck Surg; 2012 Jan; 138(1):44-9. PubMed ID: 22249628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAFV600E mutation in papillary thyroid microcarcinoma: a genotype-phenotype correlation.
    Virk RK; Van Dyke AL; Finkelstein A; Prasad A; Gibson J; Hui P; Theoharis CG; Carling T; Roman SA; Sosa JA; Udelsman R; Prasad ML
    Mod Pathol; 2013 Jan; 26(1):62-70. PubMed ID: 22918165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer.
    Kim SJ; Lee KE; Myong JP; Park JH; Jeon YK; Min HS; Park SY; Jung KC; Koo do H; Youn YK
    World J Surg; 2012 Feb; 36(2):310-7. PubMed ID: 22190222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Caveolin-1 expression in papillary thyroid carcinoma: correlation with clinicopathological parameters and BRAF mutation status.
    Paskaš S; Janković J; Marečko I; Išić Denčić T; Tatić S; Cvejić D; Savin S
    Otolaryngol Head Neck Surg; 2014 Feb; 150(2):201-9. PubMed ID: 24255086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF and KRAS mutations in papillary thyroid carcinoma in the United Arab Emirates.
    Al-Salam S; Sharma C; Afandi B; Al Dahmani K; Al-Zahrani AS; Al Shamsi A; Al Kaabi J
    PLoS One; 2020; 15(4):e0231341. PubMed ID: 32315324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role and relevance of BRAF mutations in risk stratifying patients of papillary thyroid cancers along with a review of literature.
    Krishnamurthy A; Ramshankar V; Murherkar K; Vidyarani S; Raghunandhan GC; Das A; Desai PB; Albert K
    Indian J Cancer; 2017; 54(1):372-378. PubMed ID: 29199726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma.
    Koperek O; Kornauth C; Capper D; Berghoff AS; Asari R; Niederle B; von Deimling A; Birner P; Preusser M
    Am J Surg Pathol; 2012 Jun; 36(6):844-50. PubMed ID: 22592144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The expression of monocarboxylate transporters in thyroid carcinoma can be associated with the morphological features of BRAF
    Rossi ED; Bizzarro T; Granja S; Martini M; Capodimonti S; Luca E; Fadda G; Lombardi CP; Pontecorvi A; Larocca LM; Baltazar F; Schmitt F
    Endocrine; 2017 May; 56(2):379-387. PubMed ID: 27484771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.